Immuron Ltd Files 6-K Reporting December Announcements
Ticker: IMRN · Form: 6-K · Filed: Dec 15, 2025 · CIK: 1660046
| Field | Detail |
|---|---|
| Company | Immuron LTD (IMRN) |
| Form Type | 6-K |
| Filed Date | Dec 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, regulatory-update
Related Tickers: IMRN
TL;DR
Immuron (IMRN) filed a 6-K on Dec 15, 2025, with updates from December announcements.
AI Summary
Immuron Limited, a pharmaceutical company, filed a Form 6-K on December 15, 2025, reporting on two public announcements made during December 2025. The filing indicates the company is a foreign private issuer and does not furnish information under Rule 12g3-2(b).
Why It Matters
This filing provides an update on Immuron's recent corporate communications, which may contain information relevant to investors regarding the company's ongoing operations or strategic developments.
Risk Assessment
Risk Level: low — This is a routine filing reporting on previous announcements, not containing new material financial or operational information.
Key Players & Entities
- Immuron Limited (company) — Registrant
- December 2025 (date) — Reporting period for announcements
- 001-38104 (other) — SEC File Number
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is filed by Immuron Limited to report on two public announcements made during the month of December 2025.
What is Immuron Limited's SEC file number?
Immuron Limited's SEC file number is 001-38104.
When was this Form 6-K filed?
This Form 6-K was filed on December 15, 2025.
Does Immuron Limited file annual reports under Form 20-F or 40-F?
Immuron Limited indicates it files annual reports under cover of Form 20-F.
Is Immuron Limited furnishing information under Rule 12g3-2(b)?
No, Immuron Limited is not furnishing information under Rule 12g3-2(b) as indicated by the 'No' checkbox being marked.
Filing Stats: 316 words · 1 min read · ~1 pages · Grade level 15.4 · Accepted 2025-12-15 06:32:02
Filing Documents
- ea0269670-6k_immuron.htm (6-K) — 12KB
- ea026967001ex99-1_immuron.htm (EX-99.1) — 47KB
- ea026967001ex99-2_immuron.htm (EX-99.2) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- ex99-2_001.jpg (GRAPHIC) — 17KB
- ex99-2_002.jpg (GRAPHIC) — 21KB
- 0001213900-25-121428.txt ( ) — 123KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- IMMURON LIMITED EXPLANATORY NOTE Immuron Limited (the “Company”) published two announcements (the “Public Notices”) to the Australian Securities Exchange on December 15, 2025 titled: 99.1 Application for quotation of securities 99.2 Cleansing Notice A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Application for quotation of securities 99.2 Cleansing Notice 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: December 15, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3